Tech Company Financing Transactions
Alpine Immune Sciences Funding Round
On 6/14/2016, Alpine Immune Sciences received $48 million in Series A funding from OrbiMed, Alpine Technology Fund and Frazier Healthcare Partners.
Transaction Overview
Company Name
Announced On
6/14/2016
Transaction Type
Venture Equity
Amount
$48,000,000
Round
Series A
Investors
OrbiMed (Lead Investor) (Peter Thompson)
Frazier Healthcare Partners (Jamie Toppe)
Proceeds Purpose
We believe this significant funding, along with our collective expertise, will enable us to discover and develop clinically meaningful and transformative therapies for patients.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
201 Elliott Ave. W 230
Seattle, WA 98119
USA
Seattle, WA 98119
USA
Phone
Website
Email Address
Not Recorded
Overview
Alpine Immune Sciences (AIS) was founded in 2015 and seed funded by Alpine BioVentures. AIS is focused on developing novel protein - based immunotherapies using its proprietary variant immunoglobulin domain (vIgD) platform technology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mitchell Gold
Chief Financial Officer
Paul Rickey
Chief Technical Officer
Wayne Gombotz
VP - Bus. Development
Jan Hillson
VP - R & D
Stanford Peng
VP - R & D
Kristine Swiderek
Browse more venture capital transactions:
Prev: 6/14/2016: Bipsync venture capital transaction
Next: 6/14/2016: Chronext venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs